• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Sciences >The Antiplasmodial Activity of an Herbal Antimalarial, AM 207 in Plasmodium berghei -infected Balb/c Mice: Absence of Organ Specific Toxicity
【24h】

The Antiplasmodial Activity of an Herbal Antimalarial, AM 207 in Plasmodium berghei -infected Balb/c Mice: Absence of Organ Specific Toxicity

机译：草药抗疟药AM 207在伯氏疟原虫感染的Balb / c小鼠中的抗血浆活性：没有器官特异性毒性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The antiplasmodial activity in P. berghei -infected Balb/c mice and safety in rats of the herbal antimalarial, AM 207 were investigated. The results of the 4-day parasite suppression test showed a high antiplasmodial activity of AM 207 (40 and 200 mg kg-1) comparable to that of Nibima (80 mg kg-1) and chloroquine evidenced by the similar reductions in parasitemia (6.5-6.7%) and degrees of chemo-suppression (48.3-50.6%). In the 6-day suppression test, results showed significant differences in chemo-suppression (p-1) and AM 207 at 20 and 40 mg kg-1 (35.9-52.8%) on one hand and Nibima at 40 and 200 mg kg-1 (42.6-59.2%) on the other. However, AM 207 (200 mg kg-1) and Nibima (80 mg kg-1) showed the highest chemo-suppressions (65.9-71.4%), which were comparable to that of chloroquine (86.6%). The effects of treatments on animal survival time showed that it was increased from 10 days for negative control to a maximum of 23 days for animals receiving AM 207 (20-200 mg kg-1) and 17 days for animals which received Nibima (40-200 mg kg-1). However, no deaths were recorded for chloroquine over the 23 day period. There were no adverse effects of AM 207 on selected rat organs/tissues as evidenced by absence of any significant untoward changes in haematological, urine and serum biochemical parameters as well as organ/body weights. These results indicate that AM 207 at 200 mg kg-1 exhibited antiplasmodial activity comparable to chloroquine and Nibima (80 mg kg-1) and there is no apparent organ specific toxicity associated with it on sub-chronic administration to rats.
机译：研究了伯氏疟原虫感染的Balb / c小鼠的抗血浆活性和草药抗疟药AM 207在大鼠中的安全性。 4天的寄生虫抑制试验结果显示，AM 207（40和200 mg kg -1 ）的抗疟原虫活性与Nibima（80 mg kg -1 ）相当。 SUP>）和氯喹的寄生虫血症（6.5-6.7％）和化学抑制程度（48.3-50.6％）的相似降低证明了这一点。在为期6天的抑制试验中，结果显示，在20和40 mg kg -1 时，化学抑制（p-1 ）和AM 207有显着差异（35.9-52.8％）。一方面是Nibima，另一方是40和200 mg kg -1 （42.6-59.2％）。但是，AM 207（200 mg kg -1 ）和Nibima（80 mg kg -1 ）显示最高的化学抑制（65.9-71.4％），可比比氯喹（86.6％）高。处理对动物存活时间的影响表明，从阴性对照的10天增加到接受AM 207（20-200 mg kg -1 ）的动物最多23天，从阴性对照的动物最长生存时间增加到23天。接受Nibima（40-200 mg kg -1 ）的动物。但是，在23天的时间内，没有记录到氯喹死亡的事件。 AM 207对选定的大鼠器官/组织没有不利影响，血液学，尿液和血清生化参数以及器官/体重均无任何明显的不利变化，从而证明了这一点。这些结果表明200 mg kg -1 的AM 207具有与氯喹和Nibima（80 mg kg -1 ）相当的抗血浆活性，并且没有明显的器官特异性毒性相关与亚慢性给药于大鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号